Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Henke

Vascular Surgery Ann Arbor, MI Medical Doctor

NPI 1881794618 CMS profile 221016

1500 East Medical Center Dr, 3Rd Floor Cardiovascular Center Recp B, Ann Arbor, MI 48109

Open in the dashboard

General payments

$8,285

28 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Henke of Ann Arbor, MI is reported in the CMS Open Payments database as having received $8,285 across 28 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $534 5
2024 General $473 5
2023 General $520 6
2022 General $283 2
2021 General $3,741 5
2020 General $142 2
2019 General $2,592 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Henke
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Peter Henke were reported at $534. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Peter Henke Vascular Surgery median Middle half National median
2019 $2,592 $796 $226–$2,363 $163
2020 $142 $348 $118–$1,110 $114
2021 $3,741 $471 $158–$1,421 $132
2022 $283 $725 $222–$2,183 $149
2023 $520 $836 $257–$2,440 $160
2024 $473 $909 $252–$2,619 $164
2025 $534 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Scientific Affairs, LLC $3,200 1 payment
  2. Admedus Corporation $2,375 1 payment
  3. Medtronic, Inc. $1,258 10 payments
  4. W. L. Gore & Associates, Inc. $565 4 payments
  5. HeartFlow, Inc. $293 2 payments
  6. Medtronic Vascular, Inc. $217 2 payments
  7. Silk Road Medical, Inc. $133 1 payment
  8. Endologix, Inc. $118 1 payment
  9. Bard Peripheral Vascular, Inc. $65 3 payments
  10. Surmodics, Inc. $34 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $3,200 1 payment
  2. Food and Beverage $2,710 26 payments
  3. Honoraria $2,375 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $3,213 2 payments
  2. ENDURANT IIS $791 6 payments
  3. Valiant Captivia $467 4 payments
  4. FFRct $293 2 payments
  5. GORE TAG Thoracic Endoprosthesis $248 1 payment
  6. Endurant $217 2 payments
  7. GORE VIABAHN VBX Balloon Expandable Endo $174 1 payment
  8. VIABAHN VBX Balloon Expandable Endoprosthesis $142 2 payments
  9. ENROUTE Transcarotid Neuroprotection System $133 1 payment
  10. ENROUTE Transcarotid Stent $133 1 payment
  11. Other $216 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

168

Median for Vascular Surgery: 122

Drug cost

$49,976

Median for Vascular Surgery: $14,135

Branded share of claims

33.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 33 $36,826
Eliquis Apixaban Brand 12 $10,446
Cilostazol Generic 50 $1,319
Rosuvastatin Calcium Generic 25 $472
Atorvastatin Calcium Generic 24 $407
Warfarin Sodium Generic 13 $338
Clopidogrel Clopidogrel Bisulfate Brand 11 $169

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$75,371

Medicare's payments for the services billed

Medicare patients

312

Average age 72

Services billed

513

134 women, 178 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 50%
Chronic kidney disease 49%
Diabetes 46%
Heart failure 39%
Atrial fibrillation 34%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record